FindTrial
Sign In

Evaluate the biochemical and immunological markers for the estimation of ama in the nutan & jeerna condition of amavata.

To Evaluate the Biochemical and Immunological markers for the estimation of Ama in the cases of nutan & jeerna condition of amavata with special reference to Rheumatoid Arthritis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/09/021296
Enrollment
60
Registered
2019-09-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement

Interventions

None listed

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The Patients will be grouped in two groups on the subjective basis of chronicity of disease & time duration as per the criteria given below : Group A- patient of RA having illness for a time period of less than 5 years. Group B-patient of RA having illness for a time period of above than 5 years.

Exclusion criteria

Exclusion criteria: Patient of Amavata having any other additional disease as Gout ,diabetes mellitus,Osteoarthritis, rheumatic Fever,tuberculosis,cardiac disease ,renal disease , hepatic failure etc. Pregnant & lactating women will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
develop some marker corelating to Ama in diferent stages of the disease.Timepoint: 70 days—

Secondary

MeasureTime frame
To evaluate the biochemical and immunological markers for the estimation of ama in the nutan and jeerna condition of amavata .Timepoint: 70 days—

Countries

India

Contacts

Public ContactDr Shalini Rai

All India Institute of Ayurveda

vishnuduttagrawal@gmail.com9411274542

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026